ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy

This publication has 21 references indexed in Scilit:

• erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
  International Journal of Cancer, 1998
• Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
  JNCI Journal of the National Cancer Institute, 1996
• The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
  Breast Cancer Research and Treatment, 1995
• Understanding Adjuvant Chemotherapy for Breast Cancer
  New England Journal of Medicine, 1994
• c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
  New England Journal of Medicine, 1994
• Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
  Cancer, 1994
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
  Journal of Clinical Oncology, 1992
• Correlation of Pretreatment Proliferative Activity of Breast Cancer With the Response to Cytotoxic Chemotherapy
  JNCI Journal of the National Cancer Institute, 1989